Ознакомительная версия. Доступно 26 страниц из 126
no. 5 (2011): 460-e1; Holzgreve, Wolfgang, Klaus Pietrzik, Berthold Koletzko, and Christel Eckmann-Scholz. “Adding folate to the contraceptive pill: a new concept for the prevention of neural tube defects.” The Journal of Maternal-Fetal & Neonatal Medicine 25, no. 9 (2012): 1529–1536; Wiesinger, Herbert, Urte Eydeler, Frank Richard, Dietmar Trummer, Hartmut Blode, Beate Rohde, and Konstanze Diefenbach. “Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone.” Clinical Drug Investigation 32, no. 10 (2012): 673–684.
82. Shere, Mahvash, Priya Bapat, Cheri Nickel, Bhushan Kapur, and Gideon Koren. “Motherisk rounds: the effectiveness of folate-fortified oral contraceptives in maintaining optimal folate levels to protect against neural tube defects: a systematic review.” Journal of Obstetrics and Gynaecology Canada 37, no. 6 (2015): 527–533.
83. Leeton, John. “Depression induced by oral contraception and the role of vitamin B6 in its management.” Australian and New Zealand Journal of Psychiatry 8, no. 2 (1974): 85–88; Webb, J.L. “Nutritional effects of oral contraceptive use: a review.” The Journal of Reproductive Medicine 25, no. 4 (1980): 150–156; Rose, D.P., J.E. Leklem, R.R. Brown, and C. Potera. “Effect of oral contraceptives and vitamin B6 supplements on alanine and glycine metabolism.” The American Journal of Clinical Nutrition 29, no. 9 (1976): 956–960; Rios-Avila, Luisa, Bonnie Coats, Maria Ralat, Yueh-Yun Chi, Øivind Midttun, Per M. Ueland, Peter W. Stacpoole, and Jesse F. Gregory. “Pyridoxine supplementation does not alter in vivo kinetics of one-carbon metabolism but modifies patterns of one-carbon and tryptophan metabolites in vitamin B6– insufficient oral contraceptive users.” The American Journal of Clinical Nutrition 102, no. 3 (2015): 616–625.
84. Там же; Palmery, M., A. Saraceno, A. Vaiarelli, and G. Carlomagno. “Oral contraceptives and changes in nutritional requirements.” European Review for Medical and Pharmacological Sciences 17, no. 13 (2013): 1805–1808.
85. Akinloye, O., T.O. Adebayo, O.O. Oguntibeju, D.P. Oparinde, and E.O. Ogunyemi. “Effects of contraceptives on serum trace elements, calcium and phosphorus levels.” West Indian Medical Journal 60, no. 3 (2011): 308–315; Dante, Giulia, Alberto Vaiarelli, and Fabio Facchinetti. “Vitamin and mineral needs during the oral contraceptive therapy: a systematic review.” International Journal of Reproduction, Contraception, Obstetrics and Gynecology 3, no. 1 (2016): 1–10; Hess, Frances M., Janet C. King, and Sheldon Margen. “Zinc excretion in young women on low zinc intakes and oral contraceptive agents.” The Journal of Nutrition 107, no. 9 (1977): 1610–1620.
86. Palmery, M., A. Saraceno, A. Vaiarelli, and G. Carlomagno. “Oral contraceptives and changes in nutritional requirements.” European Review for Medical and Pharmacological Sciences 17, no. 13 (2013): 1808–1810; Webb, J.L. “Nutritional effects of oral contraceptive use: a review.” The Journal of Reproductive Medicine 25, no. 4 (1980): 150–156.
87. Akinloye, O., T.O. Adebayo, O.O. Oguntibeju, D.P. Oparinde, and E.O. Ogunyemi. “Effects of contraceptives on serum trace elements, calcium and phosphorus levels.” West Indian Medical Journal 60, no. 3 (2011): 310–315.
88. Hendrickson-Jack, Lisa. “FFP 203 | The Pill Problem | Ross Pelton.” Fertility Friday Podcast. Podcast Audio, June 1, 2018. fertilityfriday.com/203.
89. International Collaboration of Epidemiological Studies of Cervical Cancer. “Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies.” The Lancet 370, no. 9599 (2007): 1609–1621; Smith, Jennifer S., Jane Green, Amy Berrington De Gonzalez, Paul Appleby, Julian Peto, Martyn Plummer, Silvia Franceschi, and Valerie Beral. “Cervical cancer and use of hormonal contraceptives: a systematic review.” The Lancet 361, no. 9364 (2003): 1159–1167; Madeleine, Margaret M., Janet R. Daling, Stephen M. Schwartz, Katherine Shera, Barbara McKnight, Joseph J. Carter, Gregory C. Wipf. “Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix.” Cancer Epidemiology and Prevention Biomarkers 10, no. 3 (2001): 171–177.
90. Hendrickson-Jack, Lisa. “FFP 095 | Cervical Cancer & The Pill | Menstrual Suppression | Cervical Dysplasia | Abnormal Pap | No More Periods? The Blessings of the Curse | Dr. Susan Rako.” Fertility Friday Podcast. Podcast Audio, September 9, 2016. fertilityfriday.com/95.
91. Braaten, Kari P., and Marc R. Laufer. “Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine.” Reviews in Obstetrics and Gynecology 1, no. 1 (2008): 2–10; Centers for Disease Control and Prevention. Genital HPV Infection Fact Sheet. (2004). Rockville, MD: CDC National Prevention Information Network.
92. Marks, Morgan, Patti E. Gravitt, Swati B. Gupta, Kai-Li Liaw, Amha Tadesse, Esther Kim, Chailert Phongnarisorn et al. “Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand.” Journal of Infectious Diseases (2011): 1509.
93. Beral, Valerie, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, and Gillian Reeves. “Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study.” The BMJ 318, no. 7176 (1999): 96–100.
94. Piyathilake, Chandrika J., Olga L. Henao, Maurizio Macaluso, Phillip E. Cornwell, Sreelatha Meleth, Douglas C. Heimburger, and Edward E. Partridge. “Folate is associated with the natural history of high-risk human papillomaviruses.” Cancer Research 64, no. 23 (2004): 8788–8793; Piyathilake, Chandrika J., Maurizio Macaluso, Ilene Brill, Douglas C. Heimburger, and Edward E. Partridge. “Lower red blood cell folate enhances the HPV-16–associated risk of cervical intraepithelial neoplasia.” Nutrition 23, no. 3 (2007): 203–210; Zhao, W., M. Hao, Y. Wang, N. Feng, Z. Wang, W. Wang, J. Wang, and L. Ding. “Association between folate status and cervical intraepithelial neoplasia.” European Journal of Clinical Nutrition (2016); Jia, W.L., L. Ding, Z.Y. Ren, T.T. Wu, W.M. Zhao, S.L. Fan, and J.T. Wang. “Effects of both folic acid, p16 protein expression and their interaction on progression of cervical cancerization.” Chinese Journal of Epidemiology 37, no. 12 (2016): 1647–1652; Hao, Min, Weihong Zhao, Lili Zhang, Honghong Wang, and Xin Yang. “Low folate levels are associated with methylation-mediated transcriptional repression of miR-203 and miR-375 during cervical carcinogenesis.” Oncology Letters 11, no. 6 (2016): 3863–3869; Li, Q.L., L. Ding, J. Nan, C.L. Liu, Z.K. Yang, F. Chen, Y.L. Liang, and J.T. Wang. “Relationship and interaction between folate and expression of methyl-CpG-binding protein 2 in cervical cancerization.” Chinese Journal of Epidemiology 37, no. 7 (2016): 985–991; Bai, Li-Xia, Jin-Tao Wang, Ling Ding, Shi-Wen
Ознакомительная версия. Доступно 26 страниц из 126
